Description
A potent histone deacetylase (HDAC) activity inhibitor. It inhibits HDAC activity in HeLa cell extracts with an IC₅₀ of 27 nM. Belinostat significantly increases acetylation of histones H3 and H4 and potently inhibits the growth of prostate cancer cell lines (IC₅₀ range from 0.5 to 2.5 µM) with cytotoxic activity preferentially against tumor cells.
PXD101 is a potent histone deacetylase (HDAC) activity inhibitor. It inhibits HDAC activity in HeLa cell extracts with an IC₅₀ of 27 nM.
Alternate Name/Synonyms: (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; Belinostat
Appearance: White solid
Formulation: N/A
CAS Number: 414864-00-9
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: N/A
Molecular Formula: C₁₅H₁₄N₂O₄S
Molecular Weight: 318.35
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (>50 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent histone deacetylase (HDAC) activity inhibitor
MDL Number: N/A
PubChem CID: 6918638
SMILES: C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO
InChi: InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+
InChi Key: NCNRHFGMJRPRSK-MDZDMXLPSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
24 months |